Lantern Pharma (LTRN) Stock Statistics & Valuation Metrics

Lantern Pharma has a market cap or net worth of $37.36M. The enterprise value is $34.86M.

Lantern Pharma has 11,184,423 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lantern Pharma’s return on equity (ROE) is -0.98 and return on invested capital (ROIC) is 0.52%.

The current PE Ratio of Lantern Pharma is ―. Lantern Pharma’s PEG ratio is -0.00001.

In the last 12 months, Lantern Pharma had revenue of 0.00 and earned -20.78M in profits. Earnings per share was -1.93K.

In the last 12 months, operating cash flow was -16.86M and capital expenditures -4.80K, giving a free cash flow of -16.86M billion.

Lantern Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Lantern Pharma upcoming earnings date is Mar 5, 2026, Before Open (Confirmed).

Lantern Pharma as a current ratio of <0.01, with Debt / Equity ratio of 1.16%

In the past 12 months, Lantern Pharma has paid 0.00 in taxes.

Lantern Pharma EV to EBITDA ratio is -1.31, with an EV/FCF ratio of -1.52.

Lantern Pharma has $12.36M in cash and marketable securities with $93.95K in debt, giving a net cash position of $12.27M billion.

Gross margin is -6.56%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Lantern Pharma is $25.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy